in normal mice, (ii) study the effects of cyclophosphamide (CY) on host resistance, (iii) document the efficacy of active and passive immunization against Pseudomonas to enhance survival of CY-treated mice, and (iv) identify the lymphoid cell type(s) responsible for restoring immunity to Pseudomonas after CY treatment.
MATERIALS AND METHODS
Mice. Experiments not involving cell transfer techniques were performed with an outbred strain of male Swiss-Webster mice, obtained from Spartan Research Animals, Inc., Haslett, Mich. All experiments involving cell transfer utilized a strain of BALB/Aj mice inbred for 10 years in these laboratories. All mice used were 7 to 10 weeks of age and were housed in stainless-steel cages in lots of 5 to 10 mice per cage.
Vaccine preparation. Pseudomonas. A whole cell vaccine was prepared from a single strain of P. aeruginosa, immunotype 3 (14) , originally isolated from a blood culture drawn from a burned patient during a septic crisis (12) . This strain, designated Ps a-3, has been shown to cross-react serologically with 76% of all P. aeruginosa strains isolated from a variety of clinical services within the University of Michigan Medical Center. It was passed serially through several mice and lyophilized in 20%o skim milk. The lyophilized organism was reconstituted with distilled water, plated on freshly prepared
Trypticase soy agar supplemented with 5% whole human blood (HBA), and allowed to incubate at 37 C for 18 suspended to give a final concentration of the desired turbidity as measured on a Klett-Summerson photoelectric colorimeter. Viability counts were done to determine the concentration per milliliter. Melted phenol was added to the bacterial suspension to give a final concentration of 0.5%. The phenolized suspension then was heated in a controlled water bath at 56 C for 2 h with frequent agitation. The vaccine was tested for aerobic and anaerobic contamination and stored at 4 C until injected in a total volume of 0.2 ml by the intraperitoneal (i.p.) route.
Serratia. A nonpigmented strain of Serratia sp., O type 10, was used for this vaccine preparation. The isolation and treatment of this strain was the same as that given for the preparation of the Ps a-3 vaccine.
Challenge strain preparation. Lyophilized Ps a-3 was reconstituted with sterile, distilled water and plated on freshly prepared HBA 24 h before use for live challenge. The organism was removed from the plate with a sterile cotton-tipped applicator, suspended in cold BSS, washed twice by centrifugation, and diluted to the desired Klett turbidity reading. A standard curve was prepared correlating Klett turbidity with viable colony counts and was used subsequently to determine challenge concentrations. All challenge organisms were injected i.p. in a total volume of 0.2 ml as soon as possible after preparation. Challenged mice were observed for deaths at least twice daily for 6 days. All deaths directly due to the challenge usually occurred within 3 days after challenge. The Ps a-3 mean lethal dose (LD.,O) for the Swiss-Webster strain was found to be 5.6 x 10' organisms and 3.9 x 107 organisms for the BALB/Aj strain.
Drugs. Cyclophosphamide powder (Cytoxan, Mead Johnson and Co., Evansville, Ind.) was dissolved in 0.15 M NaCl to give the desired concentration. Less than 1 h elapsed from reconstitution of the powder to administration to mice i.p. in a total volume of 0.2 ml.
Antibody determination. Mice were placed under ether anesthesia and exsanguinated by severing the axillary vascular plexus. The blood from each mouse was collected separately in serology test tubes and allowed to clot. After clotting, the serum was kept frozen at -30 C until titration. All titrations were performed on the same day using the same preparation of reagents for all components of a given experiment.
Serum antibody titer was determined by passive hemagglutination using 0-negative human erythrocytes (RBCs) (19) sensitized in all experiments with a 1:4 dilution of the supernatant from a single heated suspension of Ps a-3. A 24-h growth of Ps a-3 was washed from an HBA plate and suspended in 25 ml of BSS. The suspension was heated at 121 C for 1.5 h followed by vigorous agitation using a Vortex mixer for about 15 min to release the antigen from the cell surface. The suspension was centrifuged at 5,000 x g for 1.5 h to obtain a clear supernatant.
Previously washed and packed human RBCs were added to the sensitizing supernatant diluted 1:100 in BSS, and the mixture was incubated for 0.5 h at 37 C with frequent mixing. The resulting sensitized human RBCs were washed three times with BSS and resuspended after the final wash to 4% by volume. An 0.2-ml amount of this sensitized human RBC suspension was added to an equivalent volume of mouse serum serially diluted in BSS. Human serum albumin was added to 5% by volume to help buffer the system and enhance the binding capacity of the weaker antibodies. The mixture was mixed and incubated at 37 C for 2 h and observed for macroscopic hemagglutination. The titer was recorded as the reciprocal of the highest dilution of mouse serum giving positive hemagglutination.
Passive transfer of serum. Immune serum was prepared in Swiss-Webster mice by giving two vaccinations i.p. 7 days apart of either Ps a-3 or Serratia vaccine containing 109 cells/ml. The mice were exsanguinated 3 days after the last vaccination. The sera from each set of mice were pooled and assayed for hemagglutination titers to both vaccine strains. All sera were passed through a 0.45-pm Swinny filter before infusion intravenously (i.v.). Recipient Swiss-Webster mice received 0.2 ml of either normnal, anti-Ps a-3 or anti-Serratia undiluted mouse serum.
Preparation of tissue cells. Spleen cells. The spleen cells were prepared by the method of Sandberg et al. (30) . Spleens were surgically removed from 8-to 10-week-old BALB/Aj mice and immediately placed in cold BSS. They were then minced with iris scissors to a point where the spleen fragments were small enough to be transferred to Ten Broeck tissue grinders by pipette. The fragments from three spleens were pooled and ground gently in a tissue grinder. The cell suspension was passed through a double layer of surgical gauze to remove major tissue aggregates and centrifuged, and RBCs were lysed by osmotic shock in 0.05 M NaCl after resuspension in cold BSS. They were washed twice by centrifugation and finally suspended in cold BSS.
Cell viability was determined by the trypan blue dye exclusion test. If more than 13% of the tested cells were stained, the cell preparation was discarded. The Statistical determination. All statistical formulas and methods used were obtained from Hill (17) . Experiments were repeated at least twice. The significance of the differences of the means for the data was calculated from individual determinations by the Student's t test.
RESULTS
Antibody response to Pseudomonas vaccine. Five different concentrations of the phenolized Pseudomonas vaccine ranging from 2.5 x 107 to 4.0 x 108 organisms were prepared. On day 0, the five groups of 40 mice each were vaccinated i.p. with their designated vaccine concentration. Five rnice from each group were exsanguinated every other day starting on day 0 up to day 10 and their sera were collected and frozen. On day 10, the mice remaining in each vaccine group received a second vaccination with the same vaccine concentration as used initially. Five of these mice were exsanguinated either on day + 13 or + 15 after the primary vaccination. Results of this titration are shown in Fig. 1 . The antibody titers rose rapidly after 2560 Pdmono. Vocc. Conc. x 10' primary vaccination, and it is probable that the majority of these mice had had previous environmental exposure to Pseudomonas antigen. A secondary vaccination given on day 10 raised the antibody titer on day 15 about fourfold from that found on day 4. A total of 2.5 x 107 organisms again gave the poorest response, with some mice having no detectable antibody on day 13. No significant differences in the peak antibody response levels were seen among the other four concentrations used. Since the vaccine dosage of 2.0 x 108 organisms appeared to give a somewhat more sustained response than the other concentrations, it was used in all subsequent experiments.
The immunity to Pseudomonas challenge of Swiss mice previously vaccinated with the Pseudomonas vaccine was compared to the nonspecific immunity seen in mice vaccinated with another gram-negative vaccine. Mice were divided into three groups. The first group received Pseudomonas vaccine, the second, Serratia vaccine, and the third control group received normal saline. The first two vaccine groups were randomly divided into subgroups determined by their time of vaccination. The schedule was designed so that mice from each group were vaccinated with either Pseudomonas or Serratia from 2 to 20 days before challenge. All mice were challenged on the same day with 2 x 108 Pseudomonas organisms, and the results are shown in Table 1 . Pseudomonasvaccinated mice were able to survive a challenge of 2 x 108 organisms i.p. to at least 20 days post-vaccination, even though antibody levels to Pseudomonas frequently were not detectable at this time by passive hemagglutination. Serratia-vaccinated mice showed a protective response to Pseudomonas challenge on day 2; however, this response declined with time after vaccination, approaching saline control levels by day 20. It was assumed that this early protection was a nonspecific response, possibly due to the known protective effect of endotoxin in low concentrations (15) . In all subsequent challenge experiments not involving cell transfer, at least 10 days were allowed between the time of vaccination and the time of challenge to minimize the role played by nonspecific vaccine protection. Effect of CY on resistance to Pseudomonas challenge. Pseudomonas infections rarely occur in normal patients; some debilitating condition usually precedes the occurrence ofthis type of infection, rendering them more susceptible to this organism. To simulate this susceptible condition, six groups of Swiss mice were given a single dose of CY (300 mg/kg, i.p.) at various times before challenge i.p. with varying doses of Ps a-3. A seventh group served as the challenge virulence control receiving saline in place of CY. An additional group of mice receiving CY was not challenged, serving as a CY-toxicity control; none of the latter mice died during the 20-day course of the experiment. All groups to be challenged were further divided into three subgroups, each subgroup receiving one of three challenge doses. The results are shown in Table 2 . CY decreased host resistance to Pseu- domonas over the 10-day period studied, with the greatest depression occurring within the first 4 days after CY administration. By day +6, partial restoration of resistance was evident, but full recovery still was not apparent by day +10 The mice first started showing evidence of decreased resistance 24 h post-CY treatment.
By day 2, the LD-,4, had dropped below 6 x 106 colony-forming units (CFU), a one log,,, drop compared with the LD.,, for nonnal Swiss mice. Attempts to more closely define the LD-,4, produced highly variable results, possibly due to difference in degree of previous exposure to the Pseudomonas antigens.
Effect of CY on circulating leukocytes, spleen, and thymus histology in Swiss mice. Since CY is known to have a pronounced effect on hematopoiesis (13) and on the immunocompetency of mice (9, 22) , the histology ofcirculating leukocytes (WBCs), spleen, and thymus was studied at various time intervals following a single i.p. injection of CY (300 mg/kg).
To study the effect of CY on the peripheral blood leukocytes, Swiss mice received 300 mg/ kg i.p. on day 0. At 2-day intervals, five mice were removed and exsanguinated. All mice were sacrificed between 2 and 4 p.m. in an attempt to reduce the effect that the diurnal cycle may have on the cell count. WBCs and differentials were performed and the results are given in Fig. 2 . The WBC count showed a significant drop by day +1 and continued to fall, reaching the nadir by day +4. By day +8, the WBC was recovering. As noted by others (13, 18, 34) , lymphocytes were the cell type most adversely affected; polymorphonuclear WBC became the predominate cell type 24 h after CY administration and remained so for the 10-day duration of the experiment. No change could be seen in the ratio of small to large lymphocytes.
Both splenic and thymic weights decreased to roughly one-half normal 2 days after CY treat- Although normal spleen cells could produce an antibody response to Pseudomonas vaccine, the question remained whether this system could protect against a Pseudomonas challenge. Accordingly, a similar experiment was designed except that the mice were challenged 6 days after spleen cell transfer. The results are shown in Table 6 . In CY-treated mice 4.5 x 107 spleen cells were able to restore resistance. If they were vaccinated in addition to receiving the normal spleen cells, they showed greater resistance. Vaccine alone in CY-treated mice was not protective. It was concluded that cells contained within the normal spleen were sufficient to re-establish immunity to Pseudomonas in CY-treated mice when exposed to the vaccine.
(ii) Immune response to Pseudomonas vaccine in CY-treated BALB mice transfused with normal thymus and bone marrow cells before vaccination. Since the spleen contains both thymus-derived (T) and bone marrow-derived (B) cells, it was of interest to determine whether the antibody response to Pseudomonas vaccine and immunity to Pseudomonas challenge could be established in CY-treated mice receiving either normal thymus or bone marrow, or a combination ofthese cell types. Spleen and skeletal muscle cell recipients served as positive and negative controls, respectively. All mice received Pseudomonas vaccine 24 h after cell transfer. All sera were collected for antibody titration 7 days after cell transfer, and the results are shown in Table 7 .
Antibody titers in the responding mice were induced but were of low magnitude irrespective of which cell types were transferred. A significant factor, however, was the number of mice that were able to respond to the vaccine. Only 15% of the mice receiving thymus cells alone and 27% of the recipients of bone marrow cells responded. Those mice receiving both preparations, however, gave a 69% response rate.
In an attempt to render CY-treated BALB mice immune to Pseudomonas challenge, normal thymus and bone marrow cells were transfused, followed by Pseudomonas vaccination, as performed in the above experiment. The mice were challenged i.p. with Pseudomonas 6 days later. Using 6 x 107 cells of each type, significant protection was seen in all groups receiving cells irrespective ofthe type or combination used (Table 8) . Recipients of bone marrow receiving a lower concentration of cells, 1.6 x 107, were protected to a slight but insignificant degree. A combination of the two preparations had no protective effect at this lower concentration.
DISCUSSION
In our experiments, a model system has been developed which enabled study of the effects of Pseudomonas challenge in a debilitated host, where this infection normally occurs. This system revealed the following new information with respect to the pathogenesis of Pseudomonas in mice. (i) Both active Pseudomonas vaccination and passive transfer of anti-Pseudomonas immune serum rendered CY-debilitated mice immune to subsequent Pseudomonas challenge. (ii) Immunity to Pseudomonas challenge was restored in CY-treated mice by transferring either syngeneic spleen cells presensitized to Pseudomonas vaccine before challenge, or by transferring normal syngeneic spleen cells followed by in vivo sensitization with Pseudomonas vaccine before challenge. ( iii) The transfusion of 2 x 107 normal mouse syngeneic spleen cells or thymus plus bone marrow cells partially restored the ability of CY-immunosuppressed mice to respond serologically to Pseudomonas vaccine. Thymus and bone marrow cells, individually, were only marginally effective in this regard. However, this cell number was ineffective in protecting against a subsequent Pseudomonas challenge. When the number of cells administered was increased threefold, all cell types used, whether given separately or together, were able in repeat experiments to render the recipient mice immune to Pseudomonas challenge.
CY was evaluated for its ability to depress the normal resistance of mice to an i.p. challenge ofPseudomonas. When high doses of CY were given to mice, there was a significant decrease in the number of organisms necessary to kill mice (Table 2 ), but this decrease was less than might be expected. During the period of maximum suppression, the LD.,, of Pseudomonas was between 6.0 x 106 and 6.0 x 106 or about tenfold less than the LD.,, for normal mice. This depression of resistance was far less than that achieved in burned rats by McRipley and Garrison (25) where an estimated 10 Pseudomonas organisms were lethal; however, this depressed state existed for less than 72 h after burning. Repeated CY administration on day 3, as done by Dewys et al. (8) , may have increased mouse susceptibility significantly.
If immunosuppression of mice to Pseudomonas challenge with CY is due to the host's inability to produce appropriate antibody in sufficient quantities to aid phagocytic cells (5) It would be interesting to know whether peritoneal cells obtained from mice preimmunized with Pseudomonas vaccine would be able to protect against a subsequent challenge. However, it seems unlikely that the total number of phagocytic cells transferred in our experiments would, of themselves, be capable of rendering the mice immune, although they could have made a significant contribution to this protection. Markley and Smallman (24) injected both peritoneal and spleen cells into burned mice before challenging with Pseudomonas and achieved only slight protection even with repeated cell administration. However, burn wound infection may cause a more severe infec-tion which would mask the effectiveness of this form of therapy. In our model normal spleen cells could be stimulated to produce anti-Pseudomonas antibody to Pseudomonas vaccine after transfer to a CY-immunosuppressed host (Fig. 3) , and this response protected against a lethal Pseudomonas challenge (Table 6) .
Some controversy over the immunological lesion caused by CY still exists. Earlier evidence indicated that the primary lesion was in the Tcell population (1, 22) , but during the last few years the weight of the evidence indicates that the B-cell population is hardest hit. Linna et al. (21) (9) found that mouse B cells were more severely affected by CY than T cells and that the T-cell response to concanavalin A was diminished.
Stockman et al. (34) obtained similar findings using phytohemagglutinin and also could obtain no serological response to keyhole limpet hemocyanin although he could obtain cell transformation with this antigen. LaGrange et al. (20) surmised that the enhanced susceptibility of B cells over that of T cells is due to the higher turnover rate of B cells and that activated T cells would be equally sensitive. He used this differential sensitivity to advantage by showing that CY could actually enhance the development of delayed hypersensitivity to sheep RBC, a T-cell function. In our experiments, when normal mouse thymus or bone marrow cells were transfused into CY-treated recipients and subsequently vaccinated, little antibody was detected 7 days later (Table 7) . However, when these preparations were given together, a detectable antibody response was seen in a significantly greater percentage of mice. Since the antibody levels produced on cell transfer were low, this may explain why no significant protection was obtained when the recipient mice were challenged with Pseudomonas (Table 8) . By increasing the number of cells transferred, protection was achieved.
The results obtained in these experiments are consistent with the concept that CY reduced resistance to Pseudomonas by reducing the number of immunocompetent lymphoid cells capable of responding to this challenge.
Consequently, the amount of opsonizing antibody released is diminished, resulting in less efficient opsonophagocytic clearance. CY, in the dosage and frequency used, appears to cause a reduction rather than a deletion in both T and B cell types. The number of immunocompetent cells remaining in CY-treated mice, however, appears to be sufficient to be stimulated to respond to Pseudomonas vaccine by the transfusion of only thymocytes. Conversely, the capacity of the CY-treated mouse to respond with protective antibody when bone marrow cells were transfused into a thymocyte-reduced environment indicates that high numbers of bone marrow cells can overcome whatever thymic dependency Pseudomonas antigens may have. It is probable that the thymocyte population utilized herein was contaminated with small numbers of B cells present in the circulating blood, and small numbers of T cells may have been transfused with the bone marrow cell preparations. In addition, the effect of deletion of the macrophage population from these cell preparations has as yet not been analyzed. On the basis of our present results, we would hypothesize with respect to Pseudomonas that T and B cells act together to produce a more efficient antibody-forming system to these heat-stable antigens. Inasmuch as most lipopolysaccharide antigens have been shown to be thymus independent (26), the protective antigen in our experimental system may well be of a different nature.
